Volume 83, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We evaluated the incidence, severity, and duration of reactional states in 139 multibacillary (MB) leprosy patients in the first 2 years after the completion of the 1 year regimen of multidrug therapy (MDT) currently recommended by the World Health Organization (WHO) and compared those findings with 295 MB leprosy patients treated with the same regimen previously recommended for 2 years. During the first year after the completion of 1 year MDT, patients experienced 1 or more reactional states 27% of the time, the vast majority being lepra type 1 reactions (reversal reactions, RR), whereas patients who received 2 year MDT experienced a reactional state during that time period only 8% of the time ( < 0.001). Furthermore, during the first year after the completion of therapy, and during the first 2 years, both the number of reactional states and reversal reactions were significantly ( ≤ 0.004) more frequent, severe, of longer duration, and more commonly associated with neuritis.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Britton WJ, , 1998. The management of leprosy reversal reactions. Lepr Rev 69: 225234. [Google Scholar]
  2. Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DNJ, , 2001. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 69: 34133417.[Crossref] [Google Scholar]
  3. Khanolkar-Young S, Rayment N, Brickell PM, Katz DR, Vinayakumar S, Colston MJ, Lockwood DN, , 2001. Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 99: 196202.[Crossref] [Google Scholar]
  4. Manandhar R, Sherestha N, Butlin CR, Roche PW, , 2002. High levels of inflamatory cytokines are associated with poor clinical response to steriod treatment and recurrent episodes of type 1 reactions in leprosy. Clin Exp Immunol 128: 333338.[Crossref] [Google Scholar]
  5. Sarno EN, Grau GE, Vieira LM, Nery JA, , 1991. Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy ractional states. Clin Exp Immunol 84: 103108. [Google Scholar]
  6. Lienhardt C, Fine PEM, , 1994. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev 65: 933. [Google Scholar]
  7. Kumar B, Dogra S, Kaur I, , 2004. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int J Lepr Other Mycobact Dis 72: 125130.[Crossref] [Google Scholar]
  8. Schreuder PAM, , 1998. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1978–1995. II. Reactions. Int J Lepr Other Mycobact Dis 66: 159169. [Google Scholar]
  9. Lockwood DN, Vinayakumar S, Stanley JN, McAdam PW, Colston MJ, , 1993. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis 61: 815. [Google Scholar]
  10. De Rijk AJ, Gebre S, Byass P, Berhanu T, , 1994. Field evaluation of WHO-MDT of fixed duration ALERT, Ethiopia: the AMFES project, Part 2. Reactions and neuritis during and after MDT in PB and MB leprosy patients. Lepr Rev 65: 320333. [Google Scholar]
  11. Naafs B, , 1996. Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis 64: S21S28. [Google Scholar]
  12. Lockwood DN, , 1996. The management of erythema nodosum leprosum: current and future options. Lepr Rev 67: 253259. [Google Scholar]
  13. Wemambu SN, Turk JL, Waters MF, Rees RJ, , 1996. Erythema modosum leprosum. A clinical manifestation of the Arthus phenomemon. Lancet 2: 933935. [Google Scholar]
  14. Rea TH, Shen JY, Modlin RL, , 1986. Epidermal keratinocyte la expression. Langerhans cell hyperplasia and lymphocytic infiltration in skin lesions of leprosy. Clin Exp Immunol 65: 253259. [Google Scholar]
  15. Modlin RL, Hofman FM, Horowitz DA, Husmann LA, Gillis S, Taylor CR, Rea TH, , 1984. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. J Immunol 132: 30853090. [Google Scholar]
  16. Cooper CL, Mueller C, Sinchaisri TA, Pirmez C, Chan J, Kaplan G, Young SM, Weissman IL, Bloom BR, Rea TH, , 1989. Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization. J Exp Med 169: 15651581.[Crossref] [Google Scholar]
  17. Lockwood DN, Sinha HH, , 1999. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 67: 612. [Google Scholar]
  18. Jopling WH, McDougall AC, , 1996. Handbook of Leprosy. Fifth edition. New Delhi: CBS Publisher, 1047. [Google Scholar]
  19. WHO Study Group, 1982. Chemotherapy of leprosy for control programs. Geneva: World Health Organization Technical Report Series, 675. [Google Scholar]
  20. WHO Expert Committee on Leprosy, 1998. Seventh report. Geneva: World Health Organization Technical Report Series, 874. [Google Scholar]
  21. Saunderson P, Gebre S, Byass P, , 2000. Reversal reactions in the skin lesions of AMFES patients: incidence and risk factors. Lepr Rev 71: 309317. [Google Scholar]
  22. Sauderson P, Gebre S, Byass P, , 2000. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors. Lepr Rev 71: 318324. [Google Scholar]
  23. Publishing SAS, , 2004. SAS/STAT 9.1 User's Guide., Volumes 1–7. Cary, NC: SAS Institute, Inc. [Google Scholar]
  24. Publishing SAS, , 2004. SAS Online Doc 9.1.3: PDF Files. Cary, NC: SAS Institute, Inc. [Google Scholar]
  25. Taverne J, Reichlin M, Turk JL, Rees RJW, , 1976. Detection of immune complexes in mice infected with Mycobacterium lepraemurium . Clin Exp Immunol 24: 157167. [Google Scholar]
  26. Boerrigter G, Ponninghaus JM, Fine PEM, Wilson RJ, , 1991. Four years follow-up results of a WHO-recommended multidrug regimen in paucibacillary patients in Malawi. Int J Lepr Other Mycobact Dis 59: 255261. [Google Scholar]
  27. Van Brakel WH, Khawas IB, Lucas S, , 1994. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev 65: 190203. [Google Scholar]
  28. Vijaykumaran V, Manimozhi N, Jesudasan K, , 1995. Incidence of late lepra reaction among multibacillary leprosy after MDT. Int J Lepr Other Mycobact Dis 63: 1822. [Google Scholar]
  29. World Health Organization, 1994. Risk of Relapse in Leprosy. The Leprosy Unit. Division of Tropical Diseases, 94.1. Geneva: World Health Organization. [Google Scholar]
  30. Cellona RV, Balagon MV, Dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, Topolski R, Gelber RH, Eash DS, , 2003. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr Other Mycobact Dis 71: 308319.[Crossref] [Google Scholar]
  31. Gelber RH, Balagon MVF, Cellona RV, , 2004. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis 72: 493500.[Crossref] [Google Scholar]
  32. Girdhar BK, Girdhar A, Kumar A, , 2000. Relapses in multibacilliary leprosy patients: effect of length of therapy. Lepr Rev 71: 144153. [Google Scholar]
  33. Jamet P, Ji B, , 1995. Relapse after long-term follow-up of multibacillary patients treated by WGO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 63: 195201. [Google Scholar]

Data & Media loading...

  • Received : 27 Sep 2009
  • Accepted : 28 Apr 2010
  • Published online : 07 Sep 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error